| 000 | 01453 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250512141403.0 | ||
| 264 | 0 | _c19720819 | |
| 008 | 197208s 0 0 eng d | ||
| 022 | _a0008-4824 | ||
| 024 | 7 |
_a10.1177/070674377201700207 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMars, H | |
| 245 | 0 | 0 |
_aL-DOPA in Parkinson's disease. Results of a co-operative study in the Montreal area. _h[electronic resource] |
| 260 |
_bCanadian Psychiatric Association journal _cApr 1972 |
||
| 300 |
_a123-31 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBasal Ganglia Diseases _xchemically induced |
| 650 | 0 | 4 |
_aConstipation _xchemically induced |
| 650 | 0 | 4 |
_aDihydroxyphenylalanine _xadministration & dosage |
| 650 | 0 | 4 | _aEvaluation Studies as Topic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypotension _xchemically induced |
| 650 | 0 | 4 |
_aMovement Disorders _xchemically induced |
| 650 | 0 | 4 |
_aNausea _xchemically induced |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 | _aQuebec |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aVomiting _xchemically induced |
| 700 | 1 | _aLibman, I | |
| 700 | 1 | _aSchwartz, A M | |
| 700 | 1 | _aGillo-Joffroy, L | |
| 700 | 1 | _aBarbeau, A | |
| 773 | 0 |
_tCanadian Psychiatric Association journal _gvol. 17 _gno. 2 _gp. 123-31 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1177/070674377201700207 _zAvailable from publisher's website |
| 999 |
_c5038956 _d5038956 |
||